ZA201806894B - (+)-azasetron for use in the treatment of ear disorders - Google Patents

(+)-azasetron for use in the treatment of ear disorders

Info

Publication number
ZA201806894B
ZA201806894B ZA2018/06894A ZA201806894A ZA201806894B ZA 201806894 B ZA201806894 B ZA 201806894B ZA 2018/06894 A ZA2018/06894 A ZA 2018/06894A ZA 201806894 A ZA201806894 A ZA 201806894A ZA 201806894 B ZA201806894 B ZA 201806894B
Authority
ZA
South Africa
Prior art keywords
azasetron
treatment
ear disorders
ear
disorders
Prior art date
Application number
ZA2018/06894A
Other languages
English (en)
Inventor
Dyhrfjeld-Johnsen Jonas
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/059058 external-priority patent/WO2017178645A1/en
Application filed by Sensorion filed Critical Sensorion
Publication of ZA201806894B publication Critical patent/ZA201806894B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2018/06894A 2016-04-14 2018-10-16 (+)-azasetron for use in the treatment of ear disorders ZA201806894B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322690P 2016-04-14 2016-04-14
EP16180192 2016-07-19
PCT/EP2017/059058 WO2017178645A1 (en) 2016-04-14 2017-04-14 (+)-azasetron for use in the treatment of ear disorders

Publications (1)

Publication Number Publication Date
ZA201806894B true ZA201806894B (en) 2023-03-29

Family

ID=65588799

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/06894A ZA201806894B (en) 2016-04-14 2018-10-16 (+)-azasetron for use in the treatment of ear disorders

Country Status (18)

Country Link
US (2) US11612605B2 (https=)
EP (1) EP4335508A3 (https=)
JP (1) JP7158723B2 (https=)
CN (1) CN109310698B (https=)
AU (1) AU2023202897B2 (https=)
CL (1) CL2018002930A1 (https=)
DK (1) DK3442537T3 (https=)
ES (1) ES2975016T3 (https=)
FI (1) FI3442537T3 (https=)
HR (1) HRP20240453T1 (https=)
HU (1) HUE066000T2 (https=)
IL (1) IL262305B (https=)
MX (1) MX384045B (https=)
NZ (1) NZ747201A (https=)
PL (1) PL3442537T3 (https=)
RS (1) RS65379B1 (https=)
SI (1) SI3442537T1 (https=)
ZA (1) ZA201806894B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2882602T3 (es) * 2015-05-18 2021-12-02 Sensorion Azasetrón para usar en el tratamiento de la pérdida auditiva

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
GB0104554D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New uses
US20030044356A1 (en) 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
GB0213869D0 (en) 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
NZ541009A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US20040204466A1 (en) 2003-04-14 2004-10-14 Orchid Chemicals And Pharmaceuticals Ltd. Treatment of bronchial asthma using 5-HT3 receptor antagonists
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US20100016218A1 (en) 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
CN102458400B (zh) 2009-05-20 2014-10-08 国立健康与医学研究所 用于治疗病灶性前庭功能障碍的血清素5-ht3受体拮抗剂
CN101786963B (zh) 2010-03-03 2013-05-08 山东众诚药业股份有限公司 阿扎司琼中间体的合成方法
JP2015511242A (ja) 2012-02-23 2015-04-16 インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル) 病変性前庭障害の治療に使用するカルシニューリン阻害剤
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
BR112016002205A2 (pt) * 2013-07-31 2017-08-01 Bluepharma Ind Farmaceutica S A filmes orodispersíveis
CN104557906A (zh) 2015-01-21 2015-04-29 扬子江药业集团四川海蓉药业有限公司 一种盐酸阿扎司琼的制备方法
ES2882602T3 (es) * 2015-05-18 2021-12-02 Sensorion Azasetrón para usar en el tratamiento de la pérdida auditiva

Also Published As

Publication number Publication date
DK3442537T3 (da) 2024-03-25
EP4335508A3 (en) 2024-07-10
US20230226071A1 (en) 2023-07-20
NZ747201A (en) 2023-02-24
JP7158723B2 (ja) 2022-10-24
US20190083503A1 (en) 2019-03-21
JP2019513780A (ja) 2019-05-30
EP4335508A2 (en) 2024-03-13
FI3442537T3 (fi) 2024-04-04
IL262305B (en) 2022-03-01
HUE066000T2 (hu) 2024-06-28
US11612605B2 (en) 2023-03-28
IL262305A (en) 2018-11-29
HRP20240453T1 (hr) 2024-06-21
MX2018012587A (es) 2019-03-07
AU2023202897B2 (en) 2025-01-30
CL2018002930A1 (es) 2019-02-15
ES2975016T3 (es) 2024-07-02
SI3442537T1 (sl) 2024-05-31
CN109310698B (zh) 2021-12-24
MX384045B (es) 2025-03-14
PL3442537T3 (pl) 2024-07-15
RS65379B1 (sr) 2024-04-30
AU2023202897A1 (en) 2023-05-25
CN109310698A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL290150A (en) Compounds and methods for treating chronic pain
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
GB201405232D0 (en) Apparatus and methods for the treatment of ocular disorders
IL258032B (en) Compounds and preparations for the treatment of ocular disorders
PL3297628T3 (pl) Azasetron do stosowania w leczeniu niedosłuchu
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
IL270701A (en) Neurotrophins for use in the treatment of hearing loss
IL275349A (en) Use of hM4Di in the treatment of seizure disorders
IL246855A0 (en) Materials for use in the treatment of retinitis
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
IL269121A (en) Usl-311 for use in the treatment of cancer
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido
EP3226865A4 (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
GB201602011D0 (en) Treating skin disorders
LT3297628T (lt) Azasetronas, skirtas naudoti klausos praradimo gydymui
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
GB201507113D0 (en) Methods for the treatment of inflammatory disorders